Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Procept Biorobotics Corp (NQ: PRCT )

69.43 +2.59 (+3.87%)
Streaming Delayed Price Updated: 1:12 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 346,790
Open 67.85
Bid (Size) 69.40 (5)
Ask (Size) 69.55 (4)
Prev. Close 66.84
Today's Range 67.41 - 69.56
52wk Range 24.83 - 77.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
You’ve Been Warned! 3 Robotics Stocks to Buy Now or Regret Forever.
While AI is grabbing all the headlines right now, forward-thinking investors are snapping up these robotics stocks before they blast off. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+67.54%
+67.54%
1 Month
+11.91%
+11.91%
3 Month
+37.21%
+37.21%
6 Month
+47.28%
+47.28%
1 Year
+87.70%
+87.70%

More News

Read More
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
Via Benzinga
From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
PROCEPT BioRobotics's Earnings: A Preview
Via Benzinga
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
Via Investor's Business Daily
PRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
From PROCEPT BioRobotics
Via GlobeNewswire
Demystifying PROCEPT BioRobotics: Insights From 4 Analyst Reviews
Via Benzinga
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
Via Benzinga
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
Procept BioRobotics Shares Are Higher Today, CEO Touts 'Strong Surgeon Interest'
Via Benzinga
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Stock Scores Rising Relative Strength
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.